Related Experiment Video
Updated: Sep 3, 2025
Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022
Emma van Groesen1, Paolo Innocenti1, Nathaniel I Martin1
1Biological Chemistry Group, Institute of Biology Leiden, Leiden University 2333 BE Leiden, The Netherlands.
Abstract:
The accelerated appearance of drug-resistant bacteria poses an ever-growing threat to modern medicine's capacity to fight infectious diseases. Gram-positive species such as methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae continue to contribute significantly to the global burden of antimicrobial resistance. For decades, the treatment of serious Gram-positive infections relied upon the glycopeptide family of antibiotics, typified by vancomycin, as a last line of defense. With the emergence of vancomycin resistance, the semisynthetic glycopeptides telavancin, dalbavancin, and oritavancin were developed. The clinical use of these compounds is somewhat limited due to toxicity concerns and their unusual pharmacokinetics, highlighting the importance of developing next-generation semisynthetic glycopeptides with enhanced antibacterial activities and improved safety profiles. This Review provides an updated overview of recent advancements made in the development of novel semisynthetic glycopeptides, spanning the period from 2014 to today. A wide range of approaches are covered, encompassing innovative strategies that have delivered semisynthetic glycopeptides with potent activities against Gram-positive bacteria, including drug-resistant strains. We also address recent efforts aimed at developing targeted therapies and advances made in extending the activity of the glycopeptides toward Gram-negative organisms.
Insights
New semisynthetic glycopeptides show potent activity against drug-resistant Gram-positive bacteria. Research focuses on improving safety and expanding efficacy to combat the growing threat of antimicrobial resistance.
Area of Science:
- Medicinal Chemistry
- Infectious Diseases
- Pharmacology
Background:
- Antimicrobial resistance, particularly from Gram-positive bacteria like MRSA, is a major global health threat.
- Glycopeptide antibiotics, such as vancomycin, have been crucial for treating serious Gram-positive infections.
- Emergence of vancomycin resistance necessitates the development of new therapeutic agents.
Purpose of the Study:
- To review recent advancements in novel semisynthetic glycopeptide development (2014-present).
- To highlight innovative strategies yielding potent antibacterial activities against resistant Gram-positive strains.
- To discuss efforts in targeted therapies and extending glycopeptide activity to Gram-negative organisms.
Main Methods:
- Review of scientific literature published from 2014 to the present.
- Analysis of innovative synthetic strategies for novel glycopeptide derivatives.
- Evaluation of studies on antibacterial activity, toxicity, and pharmacokinetic profiles.
Main Results:
- Development of novel semisynthetic glycopeptides with potent activity against resistant Gram-positive bacteria.
- Exploration of diverse chemical modifications to enhance efficacy and safety.
- Progress in extending glycopeptide spectrum to include Gram-negative pathogens.
Conclusions:
- Next-generation semisynthetic glycopeptides offer promising solutions to combat antimicrobial resistance.
- Continued research is vital for optimizing safety and expanding the therapeutic utility of these agents.
- Further development may address infections caused by both Gram-positive and Gram-negative bacteria.
Related Concept Videos
01:30Development of Antibiotic Resistance
02:55Synthetic Biology
Golden rice
Golden rice is a genetically modified...
01:28Peptidoglycan Synthesis
01:29Microorganisms in Medicine and Therapeutics